We compared the expression levels of the immune checkpoint molecules such as LAIR1, LAG3, CTLA4, CD200R1, CD276, KIR3DL, CD80, PDCD1, LGALS9, TNFSF14, PDCD1L2G, CD86, and CD274 in high-risk and low-risk AML patients. This evidence concerns the gene CTLA4 and acute myeloid leukemia.